कंपनी का अवलोकन
Sera Prognostics, Inc. is a healthcare entity dedicated to the discovery, development, and commercialization of blood-based biomarker tests alongside predictive analytic products and services within the United States market. The company specifically operates within the Healthcare sector, focusing on the Medical Devices industry, which implies a specialization in equipment and diagnostics utilized for clinical decision-making and patient monitoring. Sera Prognostics, Inc. maintains a market capitalization of $86.90M and generates annual revenue of $81,000 while employing a workforce of 71 individuals. The substantial disparity between the company's market valuation and its minimal revenue generation indicates a capital-intensive business model where investors are pricing in future growth potential, proprietary technology assets, or significant intangible value rather than current cash flow performance.
वित्तीय स्वास्थ्य
The company reported a revenue of $81,000 over the trailing twelve months, yet it recorded a net income of $-31,928,000 and an EBITDA of $-35,680,000, revealing a severe structural inefficiency where costs drastically exceed all income streams. This massive gap between the negligible revenue of $81,000 and the net loss of $31.9 million highlights an extreme cost structure where operational expenses, likely driven by research and development or commercialization efforts, are not covered by current sales. The free cash flow stands at $-17,447,624, indicating that the company is burning cash at a rapid rate, which limits its immediate financial flexibility and necessitates ongoing capital infusion or asset liquidation to sustain operations. Margin analysis further underscores these challenges, with a gross margin of -102.5%, an operating margin of -89540.0%, and a profit margin of 0.0%, all pointing to a business model that is currently unprofitable at every level of the income statement. On the balance sheet, the company holds $39.20M in cash against $2.34M in debt, resulting in a debt-to-equity ratio of 3.10, which suggests a leveraged position where equity is significantly diluted relative to obligations despite the high absolute cash balance. The current ratio of 1.69 indicates that the company possesses sufficient current assets to cover its short-term liabilities, suggesting a degree of short-term liquidity stability amidst the operational losses. Finally, the return on equity is -51.8% and the return on assets is -26.1%, metrics that reveal that management has not yet generated value for shareholders or efficiently utilized the asset base to produce profits.
मूल्यांकन आकलन
The valuation metrics present a complex picture, with a P/E ratio (TTM) listed as N/A due to the lack of earnings and a forward P/E of -3.31, implying that the market expects future earnings to remain negative or that the current price is detached from traditional earnings multiples. The price-to-book ratio is 1.15, indicating that the stock trades at a slight premium over its book value, suggesting that the market assigns some value to the company's intangible assets or potential despite the lack of current profitability. Alternative valuation measures such as the price-to-sales ratio of 1072.83 and an EV/EBITDA of -1.40 suggest that the company is being valued almost entirely on speculative future prospects rather than historical performance or sales efficiency. The stock's price range over the last year has oscillated between a low of $1.37 and a high of $4.09, meaning the current trading price sits somewhere within this band, reflecting high volatility in investor sentiment. With a beta of 1.06, the stock exhibits price volatility that is slightly higher than the broader market, indicating that it may move more aggressively than large-cap indices in response to market fluctuations.
Growth & Income
Revenue growth year-over-year stands at -58.3%, while earnings growth is N/A, indicating that the company is currently experiencing a contraction in sales rather than expansion, which is a significant headwind for any growth-oriented investment thesis. Since the company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, it does not return capital to shareholders through distributions, instead forcing investors to rely on potential share price appreciation or capital gains. The absence of dividend payments combined with negative earnings growth implies that the company is in a phase where it must reinvest all available resources into product development or market penetration rather than providing income to investors. The overall growth and income profile is characterized by declining revenue, negative earnings, and no dividend support, presenting a high-risk, speculative investment characteristic typical of early-stage biotech or medical device firms that have yet to achieve commercial viability.